Abstract: A thrust reverser for an aircraft propulsion unit, including a movable system with cascade vanes and an actuator allowing moving a movable system between an advanced direct thrust position and a backward thrust reversal position, the system also including an inter-cascade structure for limiting buckling of the actuator, forming a channel crossed by the actuator and delimited by a cylindrical internal surface extending along a first closed directrix curve, the fixed portion of the actuator including an end equipped with an external ring for limiting buckling of the actuator, the ring having a cylindrical external surface extending along a second closed directrix curve, the first and second closed directrix curves preferably having the same shapes and being concentric while being spaced apart from one another with the same spacing.

Abstract: A thrust reverser with movable grids, includes structure for connecting, by recessing, a front frame of an outer cowl and a rear frame of the grids. The reverser includes loading structure configured to exert a stress pressing against the connecting structure, under the action of a circumferential pull of the front frame of the outer cowl or of a tightening band supported by the front frame.

Abstract: A propulsion unit includes a fairing delimiting a flow conduit for a secondary flow. This fairing comprises includes panels, at least one of which is articulated on a mast via connecting members such as clevises.

Abstract: In some aspects, the disclosure relates to compositions and methods comprising ActRII polypeptides and TßRII polypeptides to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension associated with lung disease (e.g., pulmonary hypertension associated with chronic obstructive pulmonary disease (COP)), interstitial lung disease (ILD), or combined pulmonary fibrosis and emphysema (CPFE)), particularly treating, preventing or reducing the progression rate and/or severity of one or more pulmonary hypertension associated with lung disease (e.g., pulmonary hypertension associated with chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), or combined pulmonary fibrosis and emphysema (CPFE)) associated complications.

Abstract: In some aspects, the disclosure relates to compositions and methods comprising ActRII polypeptides to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension associated with lung disease (e.g, pulmonary hypertension associated with chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), or combined pulmonary fibrosis and emphysema (CPFE)), particularly treating, preventing or reducing the progression rate and/or severity of one or more pulmonary hypertension associated with lung disease (e.g., pulmonary hypertension associated with chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), or combined pulmonary fibrosis and emphysema (CPFE)) associated complications.

Abstract: In some aspects, the disclosure relates to ActRII-ALK4 antagonists and methods of using ActRII-ALK4 antagonists to treat, prevent, or reduce the progression rate and/or severity of heart failure (HF), particularly treating, preventing or reducing the progression rate and/or severity of one or more HF-associated comorbidities. The disclosure also provides methods of using an ActRII-ALK4 antagonist to treat, prevent, or reduce the progression rate and/or severity of heart failure associated with a variety of conditions including, but not limited to, genetic cardiomyopathies, muscle wasting diseases, and muscular dystrophies.

Abstract: A propulsion assembly including an actuator connected to an outer casing of a turbomachine by a connecting structure. The connecting structure is fastened in line with a structural arm connecting the outer casing to a hub of the turbomachine, with a common fastening device, with the result that the arm can withstand loading forces of the actuator while relieving the outer casing.

Abstract: In some aspects, the disclosure relates to ActRII-ALK4 antagonists and methods of using ActRII-ALK4 antagonists to treat, prevent, or reduce the progression rate and/or severity of heart failure (HF), particularly treating, preventing or reducing the progression rate and/or severity of one or more HF-associated comorbidities. The disclosure also provides methods of using an ActRII-ALK4 antagonist to treat, prevent, or reduce the progression rate and/or severity of heart failure associated with a variety of conditions including, but not limited to, heart failure associated with aging.

Abstract: In some aspects, the disclosure relates to compositions and methods comprising variant ActRIIB polypeptides or heteromultimers thereof to treat, prevent, or reduce the progression rate and/or severity of post-capillary pulmonary hypertension (PcPH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PcPH-associated complications.

Abstract: A thrust reverser includes a jack for translational actuation of a movable part, the jack being a screw jack without an extension tube.

Abstract: A thrust reverser for a turbojet aircraft nacelle includes a fixed structure, a movable structure and an actuator. The actuator extends along a main axis and is connected by a first connection to the fixed structure and by a second connection to the movable structure for the deployment of the movable structure between a direct jet position and a reverse jet position. The actuator is also connected to the fixed structure by a third connection arranged longitudinally between the first connection and the second connection. An axis of the third connection is radially eccentric from the main axis and the third connection allows a predetermined displacement of the actuator with respect to the fixed structure.

Abstract: A thrust reverser with movable grids, includes structure for connecting, by recessing, a front frame of an outer cowl and a rear frame of the grids. The reverser includes loading structure configured to exert a stress pressing against the connecting structure, under the action of a circumferential pull of the front frame of the outer cowl or of a tightening band supported by the front frame.

Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidoes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.

Abstract: A nacelle for a propulsion assembly, the nacelle including a front internal structure having a framework formed of longitudinal beams and including removable, dismountable or retractable panels which are provided to facilitate the access for maintenance to the parts of the motor shrouded by these panels.

Abstract: In certain aspects, the present disclosure relates to methods of treating chronic liver disease, portal hypertension, primary sclerosing cholangitis, and hepatopulmonary syndrome, particularly associated clinical complications such as, for example, pulmonary fibrosis and/or interstitial lung disease (ILD), methods comprising administering T?RII antagonists comprising a heterologous domain and a truncated, ligand-binding portion of the extracellular domain of T?RII polypeptide useful to selectively antagonize a T?RII ligand. The disclosure further provides methods for treating one or more complications associated with chronic liver disease, including interstitial lung disease (ILD) and pulmonary fibrosis, with T?RII antagonists of the present disclosure.

Abstract: In certain aspects, the present disclosure relates to methods of treating Hermansky-Pudlak Syndrome (HPS) using a T?RII antagonist. In part, the disclosure provides T?RII antagonists comprising a heterologous domain and a truncated, ligand-binding portion of the extracellular domain of T?RII polypeptide useful to selectively antagonize a T?RII ligand. The disclosure further provides methods for treating one or more complications associated with HPS, including complications associated with fibrosis and/or the lung (e.g., pulmonary fibrosis, interstitial lung disease (ILD)).

Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.

Abstract: The invention relates to compounds of formula (I): or a salt thereof, wherein R1, A, L, and R2 and n are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are ?v?1 integrin inhibitors that are useful for treating tissue specific fibrosis.

Abstract: A thrust reverser for a propulsion unit, incudes movable grids, two half-assemblies forming part of a secondary stream and, at the six o'clock position, a connecting beam intended to be mounted in cantilever with a fan housing. The half-assemblies are hinged at the twelve o'clock position so as to enable their “butterfly” movement between a flight configuration and a maintenance configuration. The connecting beam includes a connecting member configured to cooperate, in the form of a tenon and groove connection, with the half-assemblies when these are in flight configuration. The reverser also includes, downstreamof the connecting member, locks capable of locking the half-assemblies in flight configuration.

Abstract: In some aspects, the disclosure relates to compositions and methods comprising ActRII polypeptides to treat, prevent, or reduce the progression rate and/or severity of pulmonary arterial hypertension, particularly treating, preventing or reducing the progression rate and/or severity of one or more pulmonary arterial hypertension associated complications.